Literature DB >> 10918253

Cutaneous silent periods in patients with Fabry disease.

N A Syed1, F Sandbrink, C A Luciano, G Altarescu, T Weibel, R Schiffmann, M K Floeter.   

Abstract

We assessed the cutaneous silent period (CSP) in 24 patients with Fabry disease with small-fiber sensory neuropathy and 12 normal subjects to test the hypothesis that small-diameter afferents are responsible for producing the CSP. Sensory nerve conduction studies and quantitative sensory testing for cold and vibration detection thresholds were also measured. Overall, Fabry patients had impaired thermal, but not vibration, detection thresholds, with greatest impairment in the feet. In the upper extremity, CSP latencies, duration, and suppression of electromyographic activity (EMG) did not differ. In the lower extremity, patients had reduced suppression of EMG during the CSP compared to normal controls. CSP durations exhibited a bimodal distribution in patients, including a subset of seven patients with durations shorter than all controls. This subset had profound loss of thermal sensation in the feet, but this was also true of some patients who had normal CSPs. Patients with shortened CSPs had modestly elevated vibration thresholds and reduced sensory potentials in comparison to patients with normal CSPs. Reduced CSPs in Fabry patients are associated with, but not entirely explained by, the severity of small-fiber neuropathy as measured by quantitative sensory testing. The possibility that large-diameter fibers provide a minor contribution to producing the CSP should be considered. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10918253     DOI: 10.1002/1097-4598(200008)23:8<1179::aid-mus4>3.0.co;2-7

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Authors:  L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Journal:  J Inherit Metab Dis       Date:  2006-07-27       Impact factor: 4.982

Review 2.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

3.  L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.

Authors:  Francesco Formaggio; Roberto Rimondini; Cecilia Delprete; Leonardo Scalia; Emilio Merlo Pich; Rocco Liguori; Ferdinando Nicoletti; Marco Caprini
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

4.  Small fiber neuropathy associated with hyperlipidemia: utility of cutaneous silent periods and autonomic tests.

Authors:  G Morkavuk; A Leventoglu
Journal:  ISRN Neurol       Date:  2014-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.